DDInter392 DDInter1819
An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia.
Tisagenlecleucel is a CD19-directed genetically modified autologous T cell immunotherapy, or a CAR-T cell therapy for B-cell acute lymphoblastic leukemia. It was granted approval by FDA in August 2017 under the market name Kymriah. Tisagenlecleucel is an immunocellular therapy that involves autologous T cells that are collected from each individual patient and genetically engineered to express a specific protein called a chimeric antigen receptor (CAR) that specifically target CD19 antigens. Modified T cells are infused back into the patient's body. These CD19-directed chimeric antigen receptors (CD19 CAR-T cells) direct the T cells to target and kill leukemia cells that express CD19 on the cell surface. In a multicenter clinical trial involving pediatric and young adult patients with relapsed or refractory B-cell precursor ALL, the overall remission rate within three months of treatment was 83 percent.
Cladribine {u} (Compound) resembles {v} (Compound) Vidarabine
Cladribine {u} (Compound) resembles {v} (Compound) Nelarabine
Cladribine {u} may lead to a major life threatening interaction when taken with {v} Azacitidine
Cladribine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Abacavir
Cladribine {u} (Compound) treats {v} (Disease) hematologic cancer
Cladribine {u} (Compound) binds {v} (Gene) PNP
Cladribine {u} (Compound) upregulates {v} (Gene) RGS2
Cladribine {u} (Compound) downregulates {v} (Gene) PLK1
Cladribine {u} (Compound) causes {v} (Side Effect) Cardiac disorder
Cladribine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Reserpine
Cladribine (Compound) resembles Vidarabine (Compound)
Cladribine (Compound) resembles Nelarabine (Compound)
Cladribine may lead to a major life threatening interaction when taken with Azacitidine
Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Abacavir
Cladribine (Compound) treats hematologic cancer (Disease)
Cladribine (Compound) binds PNP (Gene)
Cladribine (Compound) upregulates RGS2 (Gene)
Cladribine (Compound) downregulates PLK1 (Gene)
Cladribine (Compound) causes Cardiac disorder (Side Effect)
Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Reserpine